Claims for Patent: 5,614,204

Summary for Patent: 5,614,204

Title:	Angiographic vascular occlusion agents and a method for hemostatic occlusion
Abstract:	Angiographic vascular occlusion agents comprising a biopolymer alone or in combination with platelet-rich plasma. A liquid biopolymer gels in situ in contact with divalent cations. Biopolymer agent achieves permanent occlusion, biopolymer combined with the platelet-rich plasma achieves temporary or semi-permanent occlusion. The plasma is obtained from the patient\'s own blood to avoid undesirable immunogenic reactions. The occlusion agents have strong occlusive properties when injected into a bleeding vessel.
Inventor(s):	Cochrum; Kent C. (Davis, CA)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	08/377,928
Patent Claims:	1. An angiographic vascular occlusion agent injected in situ into a bleeding vessel or a site of injury comprising a biocompatible polymer selected from the group consisting of chitin, and chitosan in a mixture With alginate or with poly-L-amino acid, said polymer being able to gel in the presence of an endogenously present or exogenously added divalent cation. 2. The agent of claim 1 wherein the polymer is the chitosan in a mixture with alginate selected from the group consisting of sodium alginate, magnesium alginate, calcium alginate, barium alginate and strontium alginate. 3. The agent of claim 2 dissolved in an aqueous solution in the amount from about 0.001 to about 20%. 4. The agent of claim 3 wherein the divalent cation is calcium present endogenously or added to the solution of claim 3 in the amount from about 0.1 to 3%. 5. The agent of claim 1 wherein the polymer is chitosan in a mixture with the poly-L-amino acid selected from the group consisting of poly-L-lysine, poly-L-arginine, poly-L-glutamic acid, poly-L-histidine and poly-.alpha.-D-glutamic acid. 6. The agent of claim 5 dissolved in an aqueous solution in the amount from about 0.001 to about 30%. 7. The agent of claim 6 wherein the divalent cation is calcium present endogenously or added to the solution of claim 6 in amount from about 0.1 to about 3%. 8. The agent of claim 1 wherein the biopolymer is chitosan or chitin. 9. The agent of claim 8 wherein the chitosan is chitosan-polyamine or chitosan-cationic present in the amount from about 0.1 to about 10%. 10. An angiographic vascular occlusion agent injected in situ into a bleeding vessel or a site of injury, said agent comprising platelet-rich plasma wherein the plasma is concentrated from about 5 to about 10 times, and a biocompatible polymer selected from the group consisting of chitosan, chitin, and chitosan in a mixture with alginate, or with a poly-L-amino acid. 11. The agent of claim 10 wherein the biocompatible polymer is chitosan in a mixture with the alginate selected from the group consisting of sodium alginate, magnesium alginate, calcium alginate, barium alginate, strontium alginate and a mixture thereof. 12. The agent of claim 11 wherein a ratio of the polymer to the platelet-rich plasma is from about 0.01:99.99% to about 30:70%, w/w. 13. The agent of claim 12 causing a temporary, semi-permanent or permanent occlusion depending on the proportionate ratio of liquid composition of the biopolymer to concentrated plasma wherein the higher ratio of polymer to concentrated plasma results in a more permanent occlusion. 14. The agent of claim 13 wherein the occlusion is semi-permanent and the concentration of the biopolymer to concentrated plasma is about 20 to 30%. 15. The agent of claim 14 wherein the plasma is concentrated from about 7 to about 8 times. 16. The agent of claim 15 wherein the platelet-rich plasma is autologous. 17. The agent of claim 16 wherein the polymer is dissolved in about 0.1 to about 3% calcium chloride solution. 18. The agent of claim 17 wherein the biopolymer is dissolved in an aqueous solution. 19. The agent of claim 10 additionally containing from about 0.1 to about 3% calcium chloride. 20. The agent of claim 10 wherein the biopolymer is chitosan. 21. The agent of claim 20 wherein the chitosan is chitosan-polyamine or chitosan-cationic. 22. The method of forming an angiographic vascular occlusion comprising administering in situ to a bleeding vessel or a site of injury an aqueous solution of a biocompatible polymer selected from the group consisting of alginate, chitosan, poly-L-amino acid and a mixture thereof, said polymer being able to gel in situ in the presence of an endogenously present or exogenously added divalent cation. 23. The method of claim 22 comprising steps: (a) preparing an aqueous solution of a biocompatible polymer; (b) inserting a catheter with attached needle to a site proximate to a bleeding site, lesion, ulcer or fistula; (c) injecting the solution of the biocompatible polymer through the needle in situ; (d) effecting the gelling of the polymer through the endogenously present or added divalent cation. 24. The method of claim 23 additionally containing step (e) injecting an aqueous solution of about 0.1 to about 3% of divalent cation simultaneously with the solution of biocompatible polymer. 25. The method of claim 24 wherein the solution of biocompatible polymer additionally contains platelet-rich plasma concentrate. 26. The method of claim 25 wherein the solution of biocompatible polymer additionally contains from about 0.1 to about 3% calcium chloride. 27. The method of claim 26 wherein the platelet-rich plasma is autologous. 28. The method of claim 27 wherein the biocompatible polymer is sodium alginate, chitosan-polyamine, chitosan-cationic or poly-L-lysine. 29. The method of claim 28 wherein the biocompatible polymer is sodium alginate dissolved in sterile water or saline solution in amount from about 1 to about 10%.

Details for Patent 5,614,204

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-23